Dermatomyositis: Review and Considerations in Older Adults
Abstract
Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by prominent skin lesions, muscle weakness, and clinically heterogeneous systemic manifestations. Among patients with DM, the male-to-female ratio is 2:1. Juvenile dermatomyositis (JDM) is most prevalent between the ages of 4 and 14 years, while adult-onset dermatomyositis typically occurs between the ages of 40 and 60 years. In a population-based study conducted in Olmsted County, Minnesota, USA, the risk of DM was found to increase with age across different age groups stratified by decade. The incidence rate of DM in individuals aged ≥ 80 years was 3.2 per 100,000 person-years. Dermatomyositis in elderly patients is characterized by unique clinical manifestations, pathogenic mechanisms, and therapeutic approaches. However, discussions regarding geriatric dermatomyositis are currently limited. Therefore, this article aims to review the epidemiology, clinical features, histopathology, and pathogenesis of dermatomyositis, with a particular focus on the unique clinical characteristics of geriatric dermatomyositis.
References
Kronzer V, Kimbrough B, Crowson C, et al., 2023, Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-Based Cohort Study. Arthritis Care & Research, 75(2): 348–55.
Anderle K, Machold K, Kiener H, et al., 2022, COVID-19 as a Putative Trigger of Anti-MDA55-Associated Dermatomyositis with Acute Respiratory Distress Syndrome (ARDS) Requiring Lung Transplantation, A Case Report. BMC Rheumatology, 6(1): 42.
Chang S, Feng A, Meng W, et al., 2021, New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19. Nature Communications, 12(1): 5417.
Chen Z, Wang Y, Kuwana M, et al., 2017, HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis. The Journal of Rheumatology, 44(9): 1389–93.
Lin J, Zhang Y, Peng Q, et al., 2017, Genetic Association of HLA-DRB1 Multiple Polymorphisms with Dermatomyositis in Chinese Population. Hla, 90(6): 354–9.
Kang E, Go D, Mimori T, et al., 2019, Novel Susceptibility Alleles in HLA Region for Myositis and Myositis Specific Autoantibodies in Korean Patients. Seminar in Arthritis and Rheumatism, 49(2): 283–7.
Orrù V, Steri M, Sidore C, et al., 2020, Complex Genetic Signatures in Immune Cells Underlie Autoimmunity and Inform Therapy. Nature Genetics, 52(10): 1036–45.
Chen Z, Cao M, Plana M, et al., 2013, Utility of Anti-Melanoma Differentiation-Associated Gene 5 Antibody Measurement in Identifying Patients with Dermatomyositis and a High Risk For Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta-Analysis. Arthritis Care & Research, 65(8): 1316–24.
Dewane M, Waldman R, Lu J, 2020, Dermatomyositis: Clinical Features and Pathogenesis. Journal of the American Academy of Dermatology, 82(2): 276–81.
Xie H, Zhang D, Wang Y, et al., 2023, Risk Factors for Mortality in Patients with Anti-MDA5 Antibody-Positive Dermatomyositis: A Meta-Analysis and Systematic Review. Seminars in Arthritis and Rheumatism, 2023(62): 152231.
Didona D, Fania L, Didona B, et al., 2020, Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis. International Journal of Molecular Sciences, 21(6): 2178.
Tiniakou E, Mammen A, 2017, Idiopathic Inflammatory Myopathies and Malignancy: A Comprehensive Review. Clinical Reviews in Allergy & Immunology, 52(1): 20–33.
Maxwell S, Ross L, Oon S, et al., 2024, Muscle Biopsy Practices in the Evaluation of Idiopathic Inflammatory Myopathies: An International Survey of Expert Clinicians. Seminars in Arthritis and Rheumatism, 2024(68): 152519.
Kohsaka H, Mimori T, Kanda T, et al., 2019, Treatment Consensus for Management of Polymyositis and Dermatomyositis among Rheumatologists, Neurologists and Dermatologists. Modern Rheumatology, 29(1): 1–19.
Waldman R, Dewane M, Lu J, 2020, Dermatomyositis: Diagnosis and Treatment. Journal of the American Academy of Dermatology, 82(2): 283–96.
